Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.

Sung Yong OhWon Seog KimJin Seok KimSeok Jin KimDok Hyun YoonDeok-Hwan YangWon Sik LeeHyo Jung KimHo-Young YhimSeong Hyun JeongJong Ho WonSuee LeeJee Hyun KongSung-Nam LimJun Ho JiKyung A KwonGyeong-Won LeeJae Hoon LeeHo Sup LeeHo-Jin ShinCheolwon Suh

Published in: Cancer communications (London, England) (2019)

Rituximab-maintenance therapy following first-line R-CVP demonstrated good PFS in patients with stage III-IV MZL, in addition to a favorable toxicity profile. Trial registration clinicaltrials.gov: NCT01213095.

Keyphrases

diffuse large b cell lymphoma
phase ii study
open label
locally advanced
phase iii
study protocol
clinical trial
oxidative stress
hodgkin lymphoma
phase ii
squamous cell carcinoma
randomized controlled trial
free survival
mesenchymal stem cells
rectal cancer
placebo controlled
replacement therapy